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Abstract
Background: Five-year survival for lung cancer has remained at 16% over last several decades largely due to the
fact that over 50% of patients are diagnosed with locally-advanced or metastatic disease. Diagnosis at an earlier
and potentially curable stage is crucial. Solitary pulmonary nodules (SPNs) are common, but the difficulty lies in the
determination of which SPN is malignant. Currently, there is no convenient and reliable biomarker effective for
early diagnosis. Secretory phospholipase A2-IIa (sPLA2-IIa) is secreted into the circulation by cancer cells and may
allow for an early detection of lung cancer.
Methods: Plasma samples from healthy donors, patients with only benign SPN, and patients with lung cancer
were analyzed. Expression of sPLA2-IIa protein in lung cancer tissues was also determined.
Results: We found that the levels of plasma sPLA2-IIa were significantly elevated in lung cancer patients. The
receiver operating characteristic curve analysis, comparing lung cancer patients to patients with benign nodules,
revealed an optimum cutoff value for plasma sPLA2-IIa of 2.4 ng/ml to predict an early stage cancer with 48%
sensitivity and 86% specificity and up to 67% sensitivity for T2 stage lung cancer. Combined sPLA2-IIa, CEA, and
Cyfra21.1 tests increased the sensitivity for lung cancer prediction. High level of plasma sPLA2-IIa was associated
with a decreased overall cancer survival. sPLA2-IIa was overexpressed in almost all non-small cell lung cancer and
in the majority of small cell lung cancer by immunohistochemistry analysis.
Conclusion: Our finding strongly suggests that plasma sPLA2-IIa is a potential lung biomarker to distinguish
benign nodules from lung cancer and to aid lung cancer diagnosis in patients with SPNs.
Background
Lung cancer is the leading cause of cancer death world-
wide with 159,390 deaths in the US in 2009. This repre-
sents 30% of total cancer deaths [1]. The 5-year survival
rate is only 16%, which has not changed in three dec-
ades. One key to improving lung cancer survival is to
diagnose it at an earlier stage, given that the 5-year sur-
vival rate with stage 1A non-small cell lung cancer
( N S C L C )i sa sh i g ha s7 3 %[ 2 ] .A d v a n c e di m a g i n gt e c h -
nology and widespread availability of low dose spiral
computed tomography (LDCT) have led to a significant
increase in detection of lung nodules [3,4]. The preva-
lence of solitary pulmonary nodules (SPNs), (by defini-
tion, a SPN is < 3 cm in diameter), is 10 ~ 20%
nationwide and up to 61% in the Ohio valley [5]. The
majority of these nodules are benign, even among
patients at increased risk for lung cancer such as smo-
kers. The difficulty lies in the determination of which
SPN is malignant. An increase in the size of a SPN by
repeated CT scans is currently one important parameter
to predict the presence of malignancy [6,7]. SPNs can
be challenging to manage and costly to monitor with
radiation exposure of repeat CT scans and potential
morbidity of biopsy or surgical resection of benign
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nodule alone costs more than $20,000 [8]. Identification
of malignant nodules is crucial because they represent a
localized and potentially curable form of lung cancer. A
few plasma biomarkers have been used to screen and
diagnose cancers [9-11]. Currently, there is no single
inexpensive, convenient, and reliable biomarker proven
effective for the diagnosis of lung cancer [12].
Secretory phospholipase A2-IIa (sPLA2-IIa) is a phos-
pholipid hydrolase enzyme that mediates the release of
arachidonic acid (AA) and lysophosphatidylcholine,
which are the precursors of eicosanoids and platelet-
activating factor, respectively [13,14]. Eicosanoids are
products of both sPLA2-IIa and cyclooxygenase-2 (Cox-
2) and exert control over many physiologic processes,
such as inflammation, immunity, and tumorigenesis. It
w a sr e p o r t e dt h a te l e v a t e de i c o s a n o i d s ,s u c ha sp r o s t a -
glandins, are involved in the pathogenesis of lung cancer
[15]. sPLA2-IIa is a downstream effector of the NF-kB
gene [16,17]. A few early studies have demonstrated that
sPLA2-IIa is overexpressed in almost all human prostate
cancer specimens and elevated levels of sPLA2-IIa are
associated with tumor grade [18-20]. sPLA2-IIa remains
elevated in androgen-independent prostate cancers fail-
ing hormonal therapy and functions as a growth factor
to stimulate growth in prostate cancer cells [21].
We recently reported that elevated signaling of the
HER/HER2-PI3K-Akt-NF-kB pathway contributes to
sPLA2-IIa overexpression and secretion in prostate can-
cer cells [17,22,23]. We confirmed that sPLA2-IIa
secreted by cancer cells into the circulation to a detecT-
able level in mice carrying xenograft human tumor. We
are the first to demonstrate that there are high levels of
plasma sPLA2-IIa in prostate cancer patients, which are
associated significantly with high Gleason score and
advanced disease stage. In the present study, we
expanded our observation to lung cancer. We found
that lung cancer tissues overexpress sPLA2-IIa and high
levels of plasma sPLA2-IIa may serve as a plasma bio-
marker for lung cancer.
Methods
Patient population
The study was conducted in accordance with the
Declaration of Helsinki and the local Institutional Review
Board approved the study protocol. All the specimens for
this study were archived biospecimens with de-identified
patient information. As part of the University of Cincin-
nati Thoracic Tumor Registry, plasma samples were col-
lected pre-operatively from patients with pulmonary
nodules known or suspected to be lung cancer under-
going resection (Principal investigator: Dr. Sandra
Starnes) [5]. Data on final pathology of the resected
nodules was collected and defined as the benign nodule-
lung cancer cohort (BNLCC). Plasma samples were also
collected from lung cancer patients from the “Genetic
Epidemiology of Lung Cancer” cohort (GELCC;P I :D r .
Marshall Anderson), a familial lung cancer cohort.
Plasma samples from healthy donors were obtained from
the Cincinnati Hoxworth Blood Center.
Reagent
T h em o u s es P L A 2 - I I aa n t i b o d yi sac u s t o ma n t i b o d y
developed in our lab. Human sPLA2-IIa antibody for
Immunohistochemical (IHC) was from LifeSpan BioS-
ciences (Seattle, WA).
Enzyme-linked immunosorbent assay (ELISA)
sPLA2-IIa levels in plasma samples were determined by
ELISA kit (Catalog No. 585000, Cayman Chemical Com-
pany). All plasma samples were diluted ten times for
ELISA as described before [17]. The concentration of
sPLA2-IIa in plasma was tested in duplicate and deter-
mined against a standard curve for each ELISA assay.
ELISA kits for Carcinoembryonic Antigen (CEA) (EIA-
1871) and Cytokeratin-19 fragment (CYFRA 21.1) (EIA-
3943) were purchased from DRG International Inc.,
USA. Plasma samples were subjected to CEA and
Cyfra21.1 ELISA and quantitated against a standard
curve of each ELISA assay.
Immunohistochemical (IHC) staining
Lung disease spectrum tissue array was obtained from
Biomatrix.US (Rockville, MD). Immunohistochemistry
(IHC) for the sPLA-IIa protein was performed as
detailed in our previous studies [17,24]. Briefly, paraffin-
embedded tissue sections were deparaffinized in xylene,
rehydrated in graded alcohol, and transferred to PBS.
The slides were treated with a citric acid-based antigen-
retrieval buffer (DAKO Co., Carpinteria, CA), followed
by 3% H2O2 in methanol, incubated in blocking buffer
(5% BSA and 5% horse serum in PBS) and then in the
blocking buffer containing the primary antibody. After
washing, the slides were incubated with a biotinylated
secondary antibody (BioGenex Laboratories, San Ramon,
CA), followed by washing and incubation with the strep-
tavidin-conjugated peroxidase (BioGenex). A positive
reaction was visualized by incubating the slides with
sTable diaminobenzidine and counterstaining with Gill’s
hematoxylin (BioGenex) andm o u n t e dw i t hU n i v e r s a l
Mount mounting medium (Fisher Scientific, Pittsburgh,
PA). The intensity and extent of positive labeling for
sPLA2-IIa in tissue arrays were assessed semiquantita-
tively and scored as 0 (no staining), 1+ (weak and focal
staining in < 25% of tissue), 2+ (moderate intensity in
25-50% of tissue), 3+ (moderate intensity in > 50% of
tissue), and 4+ (strong and diffused staining in > 50% of
tissue).
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The means and standard deviations were calculated with
confirmed significant difference in plasma sPLA2-IIa
level between lung cancer specimens and benign nodule
specimens. Geometric means and standard deviations
were also calculated with confirmed significant differ-
ence in plasma sPLA2-IIa level between lung cancer
specimens and clinical control specimens. Unpaired t
test with Welch correction was performed to evaluate
the difference between sPLA2-IIa means of (i) 96 lung
cancer specimens versus 29 benign SPN specimens from
the BNLCC; (ii) 44 T1 stage lung cancer specimens ver-
sus 18 T2 stage lung cancer specimens from the
BNLCC; (iii) 44 lung cancer specimens from the
GELCC versus 29 benign SPN specimens from the
BNLCC. Unpaired t test with Welch correction was also
used to analyze overall cancer survival year associated
with plasma sPLA2-IIa level from the BNLCC.
A parametric Receiver Operating Characteristic (ROC)
analysis of plasma sPLA2-IIa values was performed to
evaluate the ability of the levels of plasma sPLA2-IIa to
distinguish 96 patients with lung cancer from 29
patients with benign SPNs from the BNLCC. 44 lung
cancer specimens from the GELCC relative to 29 benign
SPNs specimens from the BNLCC were also subjected
to the ROC analysis. The optimum cutoff value of
plasma sPLA2-IIa was determined by calculating the
Youden Index [25], which separated the combined set of
sPLA2-IIa values into two groups, such that the number
of correctly classified specimens was maximized, and the
associated sensitivity and specificity for predicting lung
cancer versus non-malignant nodule were determined.
Results
The levels of plasma sPLA2-IIa are increased in lung
cancer patients
The means and standard deviations of plasma sPLA2-IIa
levels from 96 patients with lung cancer and 29 patients
with benign lung nodules (SPNs) from the BNLCC were
3646 ± 407.3 and 1772 ± 306.8 pg/ml, respectively
(Table 1 and 2, and see Additional file 1). Based on an
unpaired t-test, the average plasma sPLA2-IIa level in
lung cancer patients was significantly higher than that in
the non-malignancy SPN controls (P = 0.004). The opti-
mum cutoff value of plasma sPLA2-IIa by ROC analysis
was 2.4 ng/ml, which resulted in 48% sensitivity and
86% specificity for predicting the presence of lung can-
c e r( F i g u r e1 aa n dT a b l e3 ) .T h ea r e au n d e rt h ec u r v e
(AUC) was 0.68 (95% CI: 0.58 ~ 0.79) (Figure 2b). We
also analyzed 44 lung cancer samples from the GELCC
in which mean and standard deviation of plasma
sPLA2-IIa were 3718 ± 407.8 (see Additional file 2). The
average plasma sPLA2-IIa level in these lung cancer
patients was also significantly higher than that in
patients with benign SPNs from the BNLCC (P =
0.003). The optimum cutoff value of plasma sPLA2-IIa
by ROC analysis was 2.4 ng/ml, which resulted in 64%
sensitivity and 86% specificity for predicting lung cancer
(AUC: 0.79; 95% CI: 0.69 ~ 0.90) (Table 3a). On the
other hand, among 20 healthy donors, the levels of
plasma sPLA2-IIa were undetecTable in 15 healthy
donors, while those of the remaining 5 donors ranged
up to 275 pg/ml (see Additional file 3). Age was not sig-
nificantly associated with the level of plasma sPLA2-IIa
in this healthy donor cohort (Table 1). ROC analysis of
the plasma sPLA2-IIa levels in 96 lung cancer samples
from the BNLCC and 20 healthy donor samples revealed
an AUC as 1.0 (95% CI: 1.0 ~ 1.0) (Figure 2a).
Further analysis revealed that plasma sPLA2-IIa was sig-
nificantly higher in T2 stage lung cancer (n =1 8 )r e l a -
tive to T1 stage lung cancer (n = 44) from the BNLCC
(Two tailed t test: P = 0.005) (Figure 1b and see Addi-
tional file 1). The optimum cutoff value of plasma
sPLA2-IIa by ROC analysis was 2.4 ng/ml, which
resulted in 67% sensitivity for predicting T2 stage lung
cancer (AUC: 0.86; 95% CI: 0.65 ~ 0.96), as compared
with 45% sensitivity for predicting T1 stage lung cancer
(Table 3a and Figure 2c). High levels of plasma sPLA2-
Table 1 Characteristics of the patients
BNLCC-Lung cancer 96
M/F 37/59
Mean age year (range) 64 (41~88)
NSCLC 93
Adenocarcinoma 54
Squamous carcinoma 21
Other NSCLC 18
SCLC 3
Stage
I4 4
II 18
III+IV 4
Blooddraw before resection 96
Blooddraw after resection 0
BNLCC-benign SPN 29
M/F 15/14
Mean age year (range) 56 (31~81)
Blooddraw before resection 29
Blooddraw after resection 0
GELCC-Lung cancer 44
M/F 18/26
Mean age year (range) 61 (47~70)
Healthy donor 20
Mean age year (range) 49 (24~65)
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(Unpaired t test with Welch correction: P = 0.0457) (see
Additional file 1). The mean overall survival year for
high sPLA2-IIa (> 2.4 ng/ml, n = 6) was 1.8 ± 1.3 years,
while the mean overall survival year for low sPLA2-IIa
(< 2.4 ng/ml, n = 11) was 3.3 ± 1.9 years.
Given the heterogeneous nature of cancer, the com-
bined blood tests including a panel of biomarkers will
increase the sensitivity for cancer prediction. Carci-
noembryonic Antigen (CEA) and Cytokeratin-19 frag-
ment (Cyfra 21.1) with the optimum cutoff value 6 ng/
ml and 3.3 ng/ml, respectively, are two best biomarkers
for predicting NSCLC currently under investigation
[12,26,27]. Positive prediction for the presence of lung
cancer by the combined blood tests was defined as one
or more biomarkers higher than their cutoff values. We
found that a combination of sPLA2-IIa (2.4 ng/ml cutoff
value), Cyfra 21.1 (3.3 ng/ml cutoff value), and CEA (6
ng/ml cutoff value) tests increased the sensitivity for
lung cancer prediction up to 62% from 48% by sPLA2-
IIa test alone for 96 cancers relative to 29 patients with
benign SPNs from the BNLCC (Table 3b and see Addi-
tional file 1 and 4). Furthermore, the combined tests
increased the sensitivity for lung cancer prediction up to
59% and 72% from 45% and 67% by sPLA2-IIa test
alone for 44 T1 stage cancers and 18 T2 stage cancers
relative to 29 patients with benign SPNs, respectively.
CEA and Cyfra 21.1 test alone had only 20% and 14%
sensitivity, respectively (Table 3b).
Among the 5 patients with benign lung nodules and
higher level of plasma sPLA2-IIa than the cutoff value
2.4 ng/ml, two patient suffered from localized pneumo-
nia, one patient suffered from myolipomatous polyp,
and the other two patients were diagnosed with
Table 2 Plasma sPLA2-IIa levels and diagnosis in patients with benign SPNs from BNLCC
Sample sPLA2-IIa (pg/ml) Diagnosis
1 1039.2 0.9 cm nodule and heavy smoker
2 1589.2 1.3 × 1.4 × 1.1 cm subpleural nodule, necrotizing granuloma
3 480.83 Nodule 2 cm
4 8980.8 Necrotizing granulomatous
5 1030.8 Nonnecrotizing granulomas
6 1105.8 Abscess colonized with fungal hyphae
7 3680.8 Nodule with organizing pneumonia pattern of lung injury
8 922.5 Caseating granulomas with emphysematous changes
9 797.5 Nodules of caseating granulomas
10 2372.5 Necrotizing granuloma with fungal organisms
11 1789.2 Peribronchial tumorlet-2 mm and focal parenchymal fibrosis
12 580.83 Necrotizing granuloma with fungal organisms
13 2305.8 Necrotizing granuloma (2 × 1.7 × 1.3 cm)
14 872.5 Broncial and broncheolar ectasis with fibrosis and chronic inflammation c/w bronchiectasis
15 2714.2 Bronchiolitis obliterans organizing pneumonia
16 714.17 Focal fibrosis and chronic inflammation and reactive pneumocyte hyperplasia
17 2105.8 Caseating granulomas with fungal elements
18 2422.17 Myolipomatous polyp
19 1226.52 Active granulomatous inflammation and possible sarcoidosis
20 2217.83 Neurofibroma, 4.5 × 3.5 cm
21 1804.78 Active non-caseating granulomas
22 430.87 Necrotizing granuloma with fungal organisms
23 3878.7 Caseating necrotizing granulomas with fungal elements
24 835.22 Non-caseating granulomas with fungal elements
25 572.5 Necrotizing granulomatous inflammation with fungal organisms consistent with Aspergillus
26 1553.75 Necrotizing granulomas with fungal yeast forms consistent with Histoplasma
27 816.25 Organizing suppurative bronchopneumonia with pleural adhesions
28 1328.75 Presented with sTable lung nodule
29 1228.13 necrotizing granuloma and Langerhans’ cell histiocytosis
*The data in bold is higher than the cutoff value of the blood test.
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that active localized inflammation can occasionally lead
to a moderate increased plasma sPLA2-IIa. Furthermore,
our data demonstrated that there was an increased basal
level of plasma sPLA2-IIa in patients with SPNs relative
to those in healthy donors, which may result from SPNs
and chronic inflammation.
Our data strongly suggest that plasma sPLA2-IIa can
serve as a biomarker to predict more than 48% of T1
stage lung cancers and up to 67% of T2 stage lung can-
cer relative to patients with benign SPNs, although the
plasma sPLA2-IIa is elevated occasionally in patients of
benign SPNs. sPLA2-IIa is the best biomarker relative to
Cyfra 21.1 and CEA, and the combined sPLA2-IIa, Cyfra
21.1 and CEA tests increase the sensitivity for lung can-
cer prediction relative to sPLA2-IIa test alone. In addi-
tion, plasma sPLA2-IIa may potentially serve as a poor
prognosis biomarker for lung cancer.
sPLA2-IIa is overexpressed in lung cancer specimens
Among 100 core lung biopsies examined by IHC,
sPLA2-IIa was overexpressed in 100% of squamous cell
carcinoma (20 cores), adenocarcinoma (20 cores), and
bronchioalveolar carcinoma (10 cores), in 70% of small
cell carcinoma (10 cores), and in 90% of metastatic
squamous cell carcinoma (10 cores) (Figure 3a-e), but
not detected in atypical carcinoid (5 cores) (Figure 3f).
sPLA2-IIa was not detected in inflammatory pseudo
tumor (5 cores), tuberculosis (5 cores), and normal lung
tissue (15 cores) (Figure 3g-h). Expression of sPLA2-IIa
in infiltrating macrophages and endothelial cells of new
blood vessels in inflammatory pseudo tumors (Figure
3g) implicated an underlying mechanism of localized
inflammation as the cause of occasional elevated levels
of plasma sPLA2-IIa in patients with benign lesions
(Table 2). We also found that sPLA2-IIa was overex-
pressed in lung cancer tissue, but not the adjacent nor-
mal type I and II epithelial cells in the spontaneous
mouse lung cancer from SP-C/TAg transgenic mice, in
which the transgene SV40 early region (TAg) gene was
driven by a 3.7 kb promoter of human surfactant pro-
t e i nC( S P - C )g e n e( F i g u r e3 i )[ 2 8 , 2 9 ] .T h e s ed a t ac o n -
firmed that sPLA1-IIa was overexpressed in lung cancer
cells, but not in normal alveolar epithelial cells.
Discussion
With increased sensitivity of imaging technology, such
as low dose spiral computed tomography (LDCT), lung
cancer can be detected at an earlier stage [2]. Recently,
lung cancer screening with CT has been shown to
detect lung tumors earlier and decrease lung cancer
mortality [30]. One of the problems with the use of CT
screening is the number of false positive with up to 25%
of the subjects in the lung cancer screening trials having
nodules, most of which are benign. Given the epidemic
of histoplasmosis in the Ohio valley, we found that
among 132 people enrolled in a pilot lung cancer
screening project, 61% of subjects had nodules, most of
which were benign [5]. If lung cancer screening with CT
becomes standard, there will be a large number of
nodules that will need to be evaluated. Monitoring these
nodules usually requires repeated CT scans at 3, 6, 9,
12, 24 months based on the sizes of SPNs [6]. An
Figure 1 High levels of plasma sPLA2-IIa are associated with
lung cancer as compared with benign lung nodule.( a) Plasma
samples were diluted ten times and then subjected to ELISA
analysis for sPLA2-IIa levels in duplicate of each sample. The average
of the duplicate samples was calculated against to the standard
curve in each experiment and presented as pg/ml sPLA2-IIa. (b)
High levels of plasma sPLA2-IIa are significantly associated with T2
lung cancer relative to T1 stage lung cancer. The dotted line
indicates the optimum cutoff value of 2.4 ng/ml
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used to predict the presence of lung cancer. This
repeated CT scan results in radiation exposure as well
as anxiety. Patients may also undergo invasive proce-
dures for diagnosis such as bronchoscopy, CT-guided
fine needle aspiration, or thoracoscopic resection. It will
become critical to have more effective ways to deter-
mine which nodules are most likely malignant.
We recently reported that there is an elevated level of
plasma sPLA2-IIa in prostate cancer patients [17]. The
current study showed that lung cancer tissues overex-
press sPLA2-IIa and that patients with lung cancer have
elevated levels of plasma sPLA2-IIa. The expression of
the sPLA2-IIa gene is not tissue-specific or cancer-speci-
fic [17]. It was reported that the levels of plasma sPLA2-
IIa are elevated with bacterial and viral infection or IL-2
infusion [31,32] and in coronary heart disease [33-35].
However, a recent clinical study including more than
500 patients showed that there is no significant altera-
tion in plasma level of sPLA2-IIa protein among
patients with coronary artery disease relative to healthy
controls [34]. In consideration of these complications,
we included some patients with inflammatory nodules
of the lung as controls. We found an increased basal
level of plasma sPLA2-IIa in these controls relative to
those in healthy donors, which may be a result of
chronic inflammation due to fungal infection and pneu-
monia. This active localized inflammation can occasion-
ally lead to a moderate increased level of plasma sPLA2-
IIa. Nevertheless, a significant high level of plasma
sPLA2-IIa as a result of lung cancer can predict more
than 48% of early stage lung cancers and up to 67% of
T2 stage lung tumors with 86% specificity. sPLA2-IIa
blood test has potential to help with the decision algo-
rithm and determine the timing of subsequent CT scans
and potential biopsy of concerning nodules.
One concern for using sPLA2-IIa as a lung cancer bio-
marker is that it lacks cancer specificity. This is one of
the common features shared by all biomarkers currently
in clinical use or under development and is simply due
to the fact that genes contributing to cancer develop-
ment overlap with those for other metabolic diseases,
Table 3 High level of plasma sPLA2-IIa predicts lung cancer
Table 3a: Determination of plasma sPLA2-IIa to predict lung cancer by ROC analysis.
Plasma sPLA2-IIa < 2.4 ng/ml > 2.4 ng/ml Total case# %Senstivity %Specificity
BNLCC lung cancer vs. benign SPN
Benign SPN 24 5 29 86
Lung cancer 50 46 96 48
Stage 1 lung cancer 24 20 44 45
Stage 2 lung cancer 6 12 18 67
GELCC lung cancer vs. benign SPN
Lung cancer 16 28 44 64
Table 3b: Combined sPLA2-IIa, CEA, and Cyfra21.1 blood tests increase the sentisitivity
to predict lung cancer.
sPLA2-IIa < 2.4 ng/ml > 2.4 ng/ml
CEA < 6.0 ng/ml > 6.0 ng/ml Total case# %Senstivity %Specificity
Cyfra21.1 < 3.3 ng/ml > 3.3 ng/ml
BNLCC lung cancer vs. benign SPN
Benign SPN 22 7 29 76
Lung cancer 36 60 96 63
Stage 1 lung cancer 18 26 44 59
Stage 2 lung cancer 5 13 18 72
CEA < 6.0 ng/ml > 6.0 ng/ml Total case# %Senstivity %Specificity
BNLCC lung cancer vs. benign SPN
Benign SPN 28 1 29 97
Lung cancer 77 19 96 20
Cyfra21.1 < 3.3 ng/ml > 3.3 ng/ml Total case# %Senstivity %Specificity
BNLCC lung cancer vs. benign SPN
Benign SPN 27 2 29 93
Lung cancer 83 13 96 14
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the sensitivity of these plasma biomarkers is usually not
very high, especially for early stages of cancer, which is
partially due to the heterogeneous nature of cancer.
Only a few plasma biomarkers are currently used to
screen and diagnose cancers in clinical practice, includ-
ing PSA, a-fetoprotein, CA19-9, CA125, and CEA
[9-11]. None of these plasma biomarkers are cancer-spe-
cific [11]. For example, PSA is tissue-specific but not
cancer-specific and has only 21% sensitivity with 4 ng/
ml as the cutoff value [36]. Plasma PSA are elevated in
benign diseases, such as in 30 ~ 50% BPH patients,
which leads to low specificity [37]. On the other hand,
many prostate cancers do not lead to a high PSA and
fail to be detected in PSA screening, which also contri-
butes to low sensitivity [37-41]. a-fetoprotein (AFP) for
hepatocellular carcinoma has 65% sensitivity and 89%
specificity, while the addition of VEGF and fucosidase
(AFU) tests can increase the sensitivity up to 100%
[42,43]. Furthermore, it is also noted that sensitivity of
plasma biomarkers, such as CA125, is increased with
advanced cancer stages, which is also consistent with
our observation of plasma sPLA2-IIa for lung cancer
[44].
A few serum biomarkers for lung cancer are cur-
rently under investigation, including Cyfra 21.1 and
CEA for NSCLC and neuron-specific enolase (NSE) for
SCLC [12,26,27]. Our data showed that none of these
lung cancer biomarkers, based on the cutoff value
reported, has high sensitivity to predict an early stage
lung cancer [45]. However, the combined test of
sPLA2-IIa, Cyfra 21.1 and CEA increases the power for
lung cancer prediction relative to sPLA2-IIa test alone.
We did not examine NSE, since there are only three
SCLC specimens in the BNLCC cohort. Although
Cyfra 21.1 is preferentially for squamous cell carci-
noma, we did not find that Cyfra 21.1 shows a high
sensitivity for squamous cell carcinoma. Given the het-
erogeneous nature of cancer and heterogeneous gene
overexpression from one cancer to another, a com-
bined blood test including a few plasma biomarkers is
essential to increase the sensitivity to predict an early
stage lung cancer.
In summary, we demonstrated that lung cancer tissues
overexpress sPLA2-IIa and there is an elevated level of
plasma sPLA2-IIa in lung cancer patients. Multiple lines
of evidence support the notion that plasma sPLA2-IIa
may represent a novel biomarker for lung cancer: 1)
sPLA2-IIa is overexpressed in all squamous cell carci-
noma, adenocarcinoma, and bronchioalveolar carcinoma
examined and in majority of small cell carcinoma; 2)
High levels of plasma sPLA2-IIa predict approximately
48% of early stage lung cancers and up to 67% of T2
stage lung cancers relative to patients with benign SPN;
3) High levels of plasma sPLA2-IIa are associated with
advanced lung cancer stages and a decreased overall
cancer survival; 4) the combined sPLA2-IIa, Cyfra 21.1
and CEA tests increase the power for lung cancer pre-
diction relative to sPLA2-IIa test alone; 5) The com-
bined lung cancer blood tests have potential to help
with the decision algorithm of lung cancer diagnosis
Figure 2 Determination of plasma sPLA2-IIa to predict lung
cancer by ROC analysis. 96 Lung cancer specimens from the
BNLCC relative to 20 healthy donors (a), 96 Lung cancer specimens
relative to 29 benign SPN specimens from the BNLCC (b), and 18 T2
stage lung cancer specimens relative to 29 benign SPN specimens
from the BNLCC were subjected to ROC analysis. Area under the
ROC curve (AUC) and 95% confidence interval (95% CI) were
determined.
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exposure.
Conclusions
This study uncovered that plasma sPLA2-IIa is a poten-
tial biomarker for lung cancer. sPLA2-IIa in combina-
tion with lung cancer biomarkers Cyfra 21.1 and CEA
will help with the decision algorithm for diagnosis of an
early stage lung cancer in patients with SPNs and poor
prognosis. Application of this combined biomarker test
will increase lung cancer survival, reduce painful and
costly resection of SPN, and reduce radiation exposure
by repeated CT exam for SPN patients.
Additional material
Additional file 1: Plasma sPLA2-IIa level in healthy donors.
Additional file 2: The levels of plasma sPLA2-IIa, Cyfra21.1, and CEA
in lung cancer patients from the BNLCC.
Additional file 3: The levels of plasma sPLA2-IIa in lung cancer
patients from the GELCC.
Additional file 4: Plasma sPLA2-IIa, Cyfra21.1, and CEA levels and
diagnosis in patients with benign SPNs from BNLCC.
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(solid arrow), but not in the adjacent normal type I and II epithelial cells (open arrow)
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